Strategic Vision Investment LTD Adagene Inc. Transaction History

Strategic Vision Investment LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.15 - $1.6 $60,856 - $84,670	-52,919 Reduced 18.11%	239,317 $366,000
Q2 2023 Jul 31, 2023	SELL	$1.17 - $1.76 $70,232 - $105,649	-60,028 Reduced 17.04%	292,236 $432,000
Q1 2023 May 10, 2023	SELL	$1.27 - $1.95 $13,208 - $20,280	-10,400 Reduced 2.87%	352,264 $510,000
Q4 2022 Feb 07, 2023	SELL	$0.9 - $1.46 $347,432 - $563,612	-386,036 Reduced 51.56%	362,664 $478,000
Q3 2022 Nov 08, 2022	SELL	$1.24 - $2.09 $37,736 - $63,604	-30,433 Reduced 3.91%	748,700 $958,000
Q1 2022 May 12, 2022	BUY	$3.5 - $8.79 $2.18 Million - $5.47 Million	622,633 Added 397.85%	779,133 $2.78 Million
Q4 2021 Feb 08, 2022	SELL	$7.4 - $14.44 $245,680 - $479,408	-33,200 Reduced 17.5%	156,500 $1.25 Million
Q2 2021 Aug 17, 2021	SELL	$11.8 - $17.87 $3.17 Million - $4.8 Million	-268,801 Reduced 58.63%	189,700 $2.57 Million
Q1 2021 May 04, 2021	BUY	$17.0 - $29.99 $7.79 Million - $13.8 Million	458,501 New	458,501 $8.23 Million

9.87M

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $89M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

Get notified when there are updates to the investment portfolio of Strategic Vision Investment LTD, based on Form 13F filings with the SEC.

Stay updated on Strategic Vision Investment LTD with notifications on news.